Abstract
Background: Few data are available regarding theeffectiveness of immune checkpoint inhibitors in advanced uppertract urothelial carcinoma (UTUC) patients. Methods: To provide a real-world experience with anti-PD-1/PD-L1-based therapy in UTUC patients, we involved an Italian network in a multicenter retrospective analysis. Results: A total of78 UTUC patients were enrolled. The median follow-up was 25.1months. The median progression-free survival (mPFS) was 2.2months (95% CI 1.8-2.6), and the median OS (mOS) was 6.0months (95% CI 3.6-8.4). The Sonpavde score (including performance status >0, hemoglobin <10g/dl, liver metastases, time from prior chemotherapy ≥3months) splitthe patients into three groups (0 vs 1 vs 2-4 factors), efficiently predicting the OS and PFS outcome at the multivariate analyses (p<0.0001). Conclusion: The prognosis of unselected UTUC patients isstill unsatisfactory. The Sonpavde score was validated for the first time in an UTUC population, as a useful tool for the treatment decision-making process.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
